209223-32-5

Basic information

• Product Name: (2R)-2-[(tert-Butoxy)carbonylaMino]-3-[(2-nitrophenyl)aMino]propanoic acid
• Synonyms: (2R)-2-[(tert-Butoxy)carbonylaMino]-3-[(2-nitrophenyl)aMino]propanoic acid;UC3;N-[(1,1-Dimethylethoxy)carbonyl]-3-[(2-nitrophenyl)amino]-D-alanine;BOC-ANPAP (2R)-2-[(tert-butoxy)carbonylamino]-3-[(2-nitrophenyl)amino]propanoic acid;(R)-(-)-2-tert-butoxycarbonylamino-3-(2-nitrophenylamino)propionic acid
• CAS NO: 209223-32-5
• Molecular Formula: C₁₄H₁₉N₃O₆
• Molecular Weight: 325.31716
• Mol File: 209223-32-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 562.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.335±0.06 g/cm3(Predicted)
• PKA: 3.65±0.10(Predicted)
• CAS DataBase Reference: (2R)-2-[(tert-Butoxy)carbonylaMino]-3-[(2-nitrophenyl)aMino]propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-2-[(tert-Butoxy)carbonylaMino]-3-[(2-nitrophenyl)aMino]propanoic acid(209223-32-5)
• EPA Substance Registry System: (2R)-2-[(tert-Butoxy)carbonylaMino]-3-[(2-nitrophenyl)aMino]propanoic acid(209223-32-5)

Safety Data

• Hazardous Substances Data: 209223-32-5(Hazardous Substances Data)

Usage

General Description

"(2R)-2-[(tert-butoxy)carbonylamino]-3-[(2-nitrophenyl)amino]propanoic acid" is a specific chemical compound that belongs to the class of organic compounds known as alpha amino acids. It is composed of a propanoic acid backbone with a tert-butoxy carbonylamino group attached to the second carbon and a 2-nitrophenylamino group attached to the third carbon. (2R)-2-[(tert-Butoxy)carbonylaMino]-3-[(2-nitrophenyl)aMino]propanoic acid is a chiral molecule, with its asymmetric carbon being in the R configuration. It is commonly used as a building block in the synthesis of pharmaceuticals and bioactive molecules due to its unique structural properties and functional groups.

Upstream product

• 76387-70-7 (S)-3-amino-2-tert-butoxycarbonylaminopropionic acid 
• 1493-27-2 ortho-nitrofluorobenzene 
• 73259-81-1 (R)-2-tert-butoxycarbonyl-3-aminopropionic acid 

Downstream Products

• 1023710-76-0 [(R)-1-[(R)-5-cyclopropylmethyl-2-oxo-1-(2,2,2-trifluoro-ethyl)-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-ylcarbamoyl]-2-(4-fluoro-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 209223-34-7 (3R)-(-)-2-oxo-3-tert-butoxycarbonylamino-5-(2-cyclohexen-1-yl)-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 
• 343326-73-8 (R)-(-)-1-tert-butylcarbonylmethyl-2-oxo-3-phenoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 
• 209219-38-5 (R)-(-)-3-[3-(1-tert-butylcarbonylmethyl-2-oxo-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-3-yl]ureido]benzoic acid 
• 343326-72-7 (R)-(-)-1-tert-butylcarbonylmethyl-2-oxo-3-amino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine oxalate 
• 209223-73-4 (R)-1-tert-butylcarbonylmethyl-2-oxo-3-tert-butoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 
• 252209-91-9 (R)-(-)-2-oxo-3-tert-butoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 
• 209223-33-6 (R)-(+)-2-oxo-3-tert-butoxycarbonylamino-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 

Relevant articles and documents

CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF

Compounds are described herein where CCK2R targeting ligands are attached to an imaging agent through a linker. The compounds can be used in the detection, diagnosis, imaging and treatment of cancer.

CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY

Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.

4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.